High-dose methylprednisolone versus dexamethasone therapy for hospitalized patients with severe COVID-19: a retrospective analysis

This study aimed to evaluate the clinical effects of high-dose methylprednisolone therapy in hospitalized patients with severe coronavirus disease (COVID-19) who required oxygen therapy, but not noninvasive/invasive mechanical ventilation or extracorporeal membrane oxygenation therapy. This retrospective observational study that was conducted from April 2021 to October 2021 at a secondary hospital in Japan enrolled patients who were administered 6 mg/day dexamethasone as an initial corticosteroid treatment on admission (dexamethasone group) and those who were administered ≥ 250 mg/day methylprednisolone (methylprednisolone group). Of the 42 participants, 40.5%(17/42) were included in the methylprednisolone group. The incidence of transfer to a tertiary hospital did not differ significantly between the methylprednisolone and dexamethasone groups (5.9% vs. 20%, p = 0.37), and in-hospital mortality was similar in both the groups (0% vs. 4%, p = 1.00). Participants in the methylprednisolone group had a significantly longer duration of oxygen therapy than the dexamethasone group (median (interquartile range) 8.5 (5.5–11.2) days vs. 4 (2.0–7.5) days, p < 0.05). Compared to dexamethasone, high-dose methylprednisolone therapy did not provide any added benefits for patients with severe COVID-19 who did not require respiratory mechanical support.

COVID-19; Severe illness; Pulse; Methylprednisolone; Dexamethasone

[1] Chilamakuri R, Agarwal S. COVID-19: characteristics and therapeutics. Cells. 2021; 10: 206.

[2] Meyerowitz EA, Richterman A, Bogoch II, Low N, Cevik M. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. The Lancet Infectious Diseases. 2021; 21: e163–e169.

[3] Jin X, Lian J, Hu J, Gao J, Zheng L, Zhang Y, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69: 1002–1009.

[4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395: 497–506.

[5] Kenny G, Mallon PW. COVID19- clinical presentation and therapeutic considerations. Biochemical and Biophysical Research Communications. 2021; 538: 125–131.

[6] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine. 2020; 180: 934.

[7] Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clinica Chimica Acta. 2020; 509: 180–194.

[8] Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis in children and adults. The Cochrane Database of Systematic Reviews. 2019; 12: Cd002243.

[9] Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine. 2021; 384: 693–704.

[10] Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal. 2020; 56: 2002808.

[11] Agarwal A, Rochwerg B, Lamontagene F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020; 370: m3379.

[12] Kory P, Kanne JP. SARS-CoV-2 organising pneumonia: ‘has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’. BMJ Open Respiratory Research. 2020; 7: e000724.

[13] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation. 2013; 48: 452–458.

[14] Matthay MA, Wick KD. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. Journal of Clinical Investigation. 2020; 130: 6218–6221.

[15] Ikeda S, Misumi T, Izumi S, Sakamoto K, Nishimura N, Ro S, et al. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study. Scientific Reports. 2021; 11: 10727.

[16] Liu J, Zhang S, Dong X, Li Z, Xu Q, Feng H, et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. Journal of Clinical Investigation. 2020; 130: 6417–6428.

[17] Wong CKH, Lau KTK, Au ICH, Xiong X, Chung MSH, Lau EHY, et al. Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone. Clinical Infectious Diseases. 2021; ciab728.

[18] Li S, Hu Z, Song X. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19. Clinical Infectious Diseases. 2021; 72: 1297–1298.

[19] Chen Y, Li L. Influence of corticosteroid dose on viral shedding duration in patients with COVID-19. Clinical Infectious Diseases. 2021; 72: 1298–1300.

[20] Buso R, Cinetto F, Dell’Edera A, Veneran N, Facchini C, Biscaro C. et al. Comparison between dexamethasone and methylprednisolone therapy in patients with COVID-19 pneumonia admitted to non-intensive medical units. Journal of Clinical Medicine. 2021; 10: 5812.

[21] Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, et al. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Scientific Reports. 2020; 10: 20935.

[22] Zhan Y, Shang J, Gu Y, Huang Q, Xie J. Efficacy of corticosteroid in patients with COVID-19: a multi-center retrospective study and meta-analysis. Journal of Medical Virology. 2021; 93: 4292–4302.

[23] Ayyar VS, Song D, DuBois DC, Almon RR, Jusko WJ. Modeling corti-costeroid pharmacokinetics and pharmacodynamics, part I: determination and prediction of dexamethasone and methylprednisolone tissue binding in the rat. Journal of Pharmacology and Experimental Therapeutics. 2019; 370: 318–326.

[24] Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infectious Diseases. 2021; 21: 337.

[25] Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. Journal of Intensive Care Medicine. 2021; 36: 673–680.

[26] Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs. methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021; 16: e0252057.

[27] Waleed K, Azizullah B, Saffa I, Saif-Eddin M, Omar S, Mohammed M, et al. Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: a systematic review and meta-analysis. Journal of Medical Virology. 2022; 1–13.

[28] Niven DJ, Gaudet JE, Laupland KB, Mrklas KJ, Roberts DJ, Stelfox HT. Accuracy of peripheral thermometers for estimating temperature: a systematic review and meta-analysis. Annals of Internal Medicine. 2015; 163: 768–777.